A short course of sirolimus [rapamycin] substantially reduces the rate of restenosis after bare-metal coronary stent implantation

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1537, 2006-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of Efficacy of Low- (80 mg/day) and High- (160-320 mg/day) Dose Valsartan in the Prevention of In-Stent Restenosis after Implantation of Bare-Metal Stents in Type B2/C Coronary Artery Lesions

By Peters Stefan  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 2, 2008-01 ,pp. : 83-87

Adis International

Access to resources Recommend Favorite

Sirolimus-eluting stent reduces restenosis, coronary events

By  

Inpharma, Vol. 1, Iss. 1342, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Sirolimus-eluting stent favourable vs bare-metal stent in STEMI

By  

Inpharma, Vol. 1, Iss. 1625, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Sirolimus-eluting stent superior to bare-metal stent in MI

By  

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Dexamethasone and Restenosis After Coronary Stent Implantation: New Indication for an Old Drug?

By  

Current Pharmaceutical Design, Vol. 10, Iss. 4, 2004-02 ,pp. : 349-355

Bentham Science Publishers

Access to resources Recommend Favorite